GHK-Cu dosing in the published literature

GHK-Cu dosage ranges reported in preclinical research

GHK-Cu dosage ranges reported in preclinical research span several orders of magnitude depending on species, route, and model. No validated human dosing protocol has been established for injectable forms; human studies have used topical formulations.

What dosage of GHK-Cu is used in research? Subcutaneous dosing in rodent models has typically ranged from 0.5 to 20 mg/kg. No validated human dosing protocol has been established; human studies have used topical formulations at 1–3% concentration.

The following ranges are drawn from published preclinical studies:

• Intraperitoneal (murine lung models): 0.2, 2, and 20 ug/g/day in cigarette smoke emphysema model over 12 weeks ^[15]; 1 and 10 ug/g in acute lung injury ^[5]; 2.6, 26, and 260 ug/ml/day in bleomycin pulmonary fibrosis model, every other day from days 4–21 ^[6].
• Intranasal (murine brain models): 15 mg/kg daily for 8 weeks in aging mice ^[19]; 15 mg/kg three times per week for 12 weeks in Alzheimer's transgenic mice ^[17].
• In vitro (collagen synthesis): 10^-9 M (1 nanomolar) for maximum collagen synthesis stimulation in human fibroblasts ^[1].
• Topical human RCTs: 1–3% topical concentration in skin studies; GHK/5-ALA spray (ALAVAX 50 or 100 mg/ml) in 6-month scalp hair loss trial ^[11].
• Hypothetical systemic dose (Pickart): 100–200 mg total estimated therapeutic systemic dose, proposed conceptually; not validated in any published RCT.

The gap between rodent intraperitoneal doses (which, when scaled by kg body weight, correspond to large systemic exposures) and the topical human studies is substantial. Allometric scaling is not a validated route to human dosing for this compound.

GHK-Cu pharmacokinetics and half-life

What is the half-life of GHK-Cu after injection? Published pharmacokinetic data for injectable GHK-Cu in humans are absent. Plasma half-life has not been formally characterized. Endogenous GHK plasma levels decline with age from approximately 200 ng/mL (20s) to near 80 ng/mL (60s) ^[16].

The compound is highly hydrophilic (log D -2.38 to -2.49), which improves aqueous stability but limits transdermal penetration. GHK-Cu is stable at pH 4.5–7.4 for two or more weeks at 60 degrees C. Lyophilized powder is typically stored at -20 degrees C long-term; reconstituted solutions stored at 4 degrees C short-term.

The question of what route delivers meaningful systemic exposure in humans is unresolved. Topical application to the stratum corneum has been measured: a 2010 ex vivo cadaver skin study showed a permeability coefficient of 2.43 +/- 0.51 x 10^-4 cm/h with 136.2 +/- 17.5 ug/cm2 copper permeating 1 cm2 of tissue over 48 hours; the stratum corneum accumulated 438x the baseline copper concentration and retained 97 ug/cm2 in skin layers ^[14]. Authors concluded topical copper tripeptide may offer a route with meaningful local delivery.

For injectable systemic exposure, no published pharmacokinetic data exist in humans. Intranasal delivery achieved central nervous system effects in mouse models at 15 mg/kg ^[17][19], suggesting this route bypasses the blood-brain barrier in rodents — but human intranasal pharmacokinetics for GHK-Cu have not been characterized.

Topical vs. injectable GHK-Cu: route of administration in research

What is the difference between topical and injectable GHK-Cu? Topical GHK-Cu has been the primary subject of published human research, with absorption through the stratum corneum being the limiting factor. Injectable research is almost entirely preclinical; systemic exposure and tissue distribution differ substantially.

Topical human research is the mature branch. Skin cream studies (two 12-week RCTs, 41 and 71 women) showed significant anti-photoaging effects ^[7]. Scalp spray application produced significant hair count increases in a 6-month RCT ^[11]. Ex vivo penetration data quantify how much copper actually reaches the dermis ^[14].

A 2025 liposomal formulation study identified the stratum corneum barrier as the key limiting factor for topical bioavailability of hydrophilic GHK-Cu (log D -2.38 to -2.49). Liposomal encapsulation efficiencies of 20–32% were demonstrated, but in vivo skin permeation of liposomal GHK-Cu remains an active and unresolved research gap ^[23].

Injectable research is exclusively preclinical: intraperitoneal in rodent lung and wound models, intranasal in brain-aging models. No published human pharmacokinetic, bioavailability, or safety data for any injected form of GHK-Cu exist.

GHK-Cu reconstitution and storage in research settings

How should GHK-Cu be reconstituted and stored? GHK-Cu lyophilized powder is typically reconstituted with bacteriostatic water at neutral to slightly acidic pH. Research-grade storage is recommended at -20 degrees C long-term; reconstituted solutions degrade faster and are stored at 4 degrees C short-term.

The compound's hydrophilicity (log D -2.38) means it dissolves readily in aqueous media, which simplifies reconstitution compared to more lipophilic peptides. Stability has been confirmed across pH 4.5–7.4 at elevated temperature (two weeks at 60 degrees C), suggesting robustness under normal storage conditions ^[23].

GHK-Cu cycling protocols in published research

What cycling protocol is recommended for GHK-Cu research? No peer-reviewed publication establishes a human cycling protocol for GHK-Cu. Preclinical animal studies have used continuous dosing over 4–12 week windows without cycling. Community protocols are not endorsed by the scientific literature.

Animal studies have used continuous daily or every-other-day dosing for durations ranging from 8 days (acute lung injury model ^[5]) to 12 weeks (emphysema and Alzheimer's models ^[15][17]). No washout periods were built into these models. The absence of cycling protocols in preclinical research reflects that no receptor downregulation or tolerance mechanism for GHK-Cu has been described — but also that long-term rodent safety studies specifically examining cessation and restart effects have not been published.

GHK-Cu Safety Profile and Observed Side Effects in Research

What are the negative side effects of GHK-Cu? Topical application studies report minimal adverse effects. Injectable forms have not been systematically studied for adverse effects in humans. Potential copper accumulation is a theoretical concern noted in the literature.

Across the published topical human studies — two 12-week skin RCTs ^[7] and one 6-month scalp spray RCT ^[11] — no significant adverse events were reported. The 5-ALA + GHK combination spray study explicitly noted no adverse events at either dose.

The primary theoretical safety concern is copper accumulation with prolonged systemic dosing. Copper is an essential trace element with a narrow therapeutic window; chronic excess copper is associated with hepatotoxicity and neurological effects. No published toxicology study for injectable GHK-Cu in humans exists to quantify this risk. The 2024 Min et al. study adds nuance: GHK actually prevents copper(II)-induced cell death in CNS cells by blocking copper redox activity and preventing protein misfolding — suggesting the tripeptide itself buffers against copper toxicity at the cellular level rather than exacerbating it ^[20].

What are the documented limitations of GHK-Cu research? Key limitations include predominance of in vitro and rodent data, no large-scale human RCTs for any systemic indication, unclear optimal dosing, and limited pharmacokinetic characterization of injectable forms in humans.

GHK-Cu compatibility and contraindications in research protocols: Research protocols note potential incompatibility with strong chelating agents that compete for copper binding. Vitamin C at high concentrations may interfere with copper bioavailability in topical formulations, as it can reduce copper(II) to copper(I), which binds GHK with lower affinity. No human interaction studies have been published.